Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.81 +8.2%	$0.97	$0.71 ▼ $2.20	$29.31M	0.89	78,030 shs	83,956 shs
NNVC NanoViricides	$1.55 +3.0%	$1.51	$0.94 ▼ $2.34	$24.83M	0.96	244,675 shs	179,979 shs
SBFM Sunshine Biopharma	$1.47 -1.7%	$1.51	$1.17 ▼ $3.90	$6.68M	1.45	640,532 shs	21,295 shs
TENX Tenax Therapeutics	$5.90 -1.3%	$5.92	$3.25 ▼ $7.89	$26.88M	1.46	28,913 shs	9,575 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	0.00%	-20.14%	-23.16%	-29.41%	-43.31%
NNVC NanoViricides	0.00%	-5.06%	-10.71%	+2.74%	-30.88%
SBFM Sunshine Biopharma	0.00%	+6.42%	-4.49%	-0.01%	-48.98%
TENX Tenax Therapeutics	0.00%	+1.02%	+0.17%	-0.83%	+42.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYAI Dyadic International	3.3797 of 5 stars	3.5	5.0	2.4	3.3	0.0
NNVC NanoViricides	0.3065 of 5 stars	0.0	5.0	0.6	0.0	0.0
SBFM Sunshine Biopharma	2.3656 of 5 stars	3.5	3.0	1.9	0.8	0.6
TENX Tenax Therapeutics	1.9159 of 5 stars	3.6	1.0	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYAI Dyadic International	3.00	Buy	$6.00	640.74% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A
SBFM Sunshine Biopharma	3.00	Buy	$15.00	923.89% Upside
TENX Tenax Therapeutics	3.25	Buy	$17.00	188.38% Upside

Current Analyst Ratings Breakdown

Latest SBFM, DYAI, NNVC, and TENX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYAI Dyadic International	$3.42M	8.57	N/A	N/A	$0.08 per share	10.13
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
SBFM Sunshine Biopharma	$34.87M	0.19	N/A	N/A	$9.10 per share	0.16
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$26.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A
SBFM Sunshine Biopharma	-$5.13M	-$150.88	N/A	∞	N/A	-17.35%	-26.04%	-20.72%	11/3/2025 (Estimated)
TENX Tenax Therapeutics	-$17.60M	-$0.92	N/A	N/A	N/A	N/A	-31.34%	-30.39%	N/A

Latest SBFM, DYAI, NNVC, and TENX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/13/2025	Q2 2025	TENX Tenax Therapeutics	-$0.50	-$0.27	+$0.23	-$0.27	N/A	N/A
8/12/2025	Q2 2025	SBFM Sunshine Biopharma	-$0.11	-$0.39	-$0.28	-$0.39	$12.10 million	$9.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
SBFM Sunshine Biopharma	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYAI Dyadic International	5.40	2.02	2.02
NNVC NanoViricides	N/A	3.44	2.47
SBFM Sunshine Biopharma	N/A	5.00	2.66
TENX Tenax Therapeutics	N/A	41.89	41.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYAI Dyadic International	27.95%
NNVC NanoViricides	10.30%
SBFM Sunshine Biopharma	41.98%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
DYAI Dyadic International	29.50%
NNVC NanoViricides	4.60%
SBFM Sunshine Biopharma	0.10%
TENX Tenax Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable
SBFM Sunshine Biopharma	3	4.56 million	4.55 million	Not Optionable
TENX Tenax Therapeutics	9	4.56 million	4.39 million	Not Optionable

SBFM, DYAI, NNVC, and TENX Headlines

Recent News About These Companies

Q3 EPS Estimate for Tenax Therapeutics Reduced by Analyst

August 18 at 2:43 AM | americanbankingnews.com

Equities Analysts Set Expectations for TENX FY2028 Earnings

August 17 at 3:19 AM | americanbankingnews.com

Tenax Posts Wider Loss in Fiscal Q2

August 14, 2025 | aol.comA

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

August 14, 2025 | msn.com

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103

March 5, 2025 | markets.businessinsider.com

Tenax Therapeutics prices 378,346 shares at $6.04 in private placement

March 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM, DYAI, NNVC, and TENX Company Descriptions

Dyadic International NASDAQ:DYAI

$0.81 +0.06 (+8.25%)

As of 02:56 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

NanoViricides NYSE:NNVC

$1.54 +0.05 (+3.00%)

As of 02:57 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Sunshine Biopharma NASDAQ:SBFM

$1.46 -0.02 (-1.67%)

As of 02:27 PM Eastern

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

Tenax Therapeutics NASDAQ:TENX

$5.90 -0.08 (-1.26%)

As of 02:52 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time